Literature DB >> 30811973

Comprehensive proteomic and metabolomic profiling of mcr-1-mediated colistin resistance in Escherichia coli.

Hui Li1, Yingyu Wang2, Qingshi Meng3, Yang Wang4, Guoliang Xia5, Xi Xia6, Jianzhong Shen7.   

Abstract

Spread of the mcr-1 gene in human and veterinary medicine has jeopardised the use of polymyxins, last-resort antibiotics against life-threatening multidrug-resistant Gram-negative bacteria. As a lipid-modifying gene, whether mcr-1 causes proteomic and metabolomic changes in bacteria and affects the corresponding metabolic pathway is largely unknown. In this study, label-free quantitative proteomics and untargeted metabolomics were used to profile comprehensive proteome and metabolome characteristics of mcr-1-mediated colistin-resistant and -susceptible Escherichia coli in order to gain further insight into the colistin resistance mechanism. Large sets of differentially expressed proteins (DEPs) and metabolites were identified that contributed to mcr-1-mediated antimicrobial resistance, predominantly in different growth conditions with and without colistin. mcr-1 caused downregulated expression of most proteins in order to adapt to drug pressure. Pathway analysis showed that metabolic processes were significantly affected, mainly related to glycerophospholipid metabolism, thiamine metabolism and lipopolysaccharide (LPS) biosynthesis. The substrate phosphoethanolamine (PEA) for mcr-1 to mediate colistin resistance was accumulated in colistin-resistant E. coli. Notably, mcr-1 not only caused PEA modification of the bacterial cell membrane lipid A but also affected the biosynthesis and transport of lipoprotein in colistin resistance by disturbing the expression of efflux pump proteins involved in the cationic antimicrobial peptide (CAMP) resistance pathway. Overall, disturbed glycerophospholipid metabolism and LPS biosynthesis as well as accumulation of the substrate PEA was closely related with mcr-1-mediated colistin resistance. These findings could provide further valuable information to inhibit colistin resistance by blocking this metabolic process.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimicrobial resistance; Colistin; Metabolomic; Proteomic; mcr-1

Mesh:

Substances:

Year:  2019        PMID: 30811973     DOI: 10.1016/j.ijantimicag.2019.02.014

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  5 in total

1.  mcr-1 Gene Expression Modulates the Inflammatory Response of Human Macrophages to Escherichia coli.

Authors:  Giorgio Mattiuz; Sabrina Nicolò; Alberto Antonelli; Tommaso Giani; Ilaria Baccani; Antonio Cannatelli; Ann Maria Clemente; Giuseppe Castronovo; Michele Tanturli; Federico Cozzolino; Gian Maria Rossolini; Maria Gabriella Torcia
Journal:  Infect Immun       Date:  2020-07-21       Impact factor: 3.441

Review 2.  Proteomic Applications in Antimicrobial Resistance and Clinical Microbiology Studies.

Authors:  Ehsaneh Khodadadi; Elham Zeinalzadeh; Sepehr Taghizadeh; Bahareh Mehramouz; Fadhil S Kamounah; Ehsan Khodadadi; Khudaverdi Ganbarov; Bahman Yousefi; Milad Bastami; Hossein Samadi Kafil
Journal:  Infect Drug Resist       Date:  2020-06-16       Impact factor: 4.003

Review 3.  Emerging Transcriptional and Genomic Mechanisms Mediating Carbapenem and Polymyxin Resistance in Enterobacteriaceae: a Systematic Review of Current Reports.

Authors:  Masego Mmatli; Nontombi Marylucy Mbelle; Nontuthuko E Maningi; John Osei Sekyere
Journal:  mSystems       Date:  2020-12-15       Impact factor: 6.496

4.  Cell Membrane Remodeling Mediates Polymyxin B Resistance in Klebsiella pneumoniae: An Integrated Proteomics and Metabolomics Study.

Authors:  Xinyi Chen; Jingjing Tian; Can Luo; Xiaofan Wang; Xianping Li; Min Wang
Journal:  Front Microbiol       Date:  2022-02-10       Impact factor: 5.640

Review 5.  A How-To Guide for Mode of Action Analysis of Antimicrobial Peptides.

Authors:  Ann-Britt Schäfer; Michaela Wenzel
Journal:  Front Cell Infect Microbiol       Date:  2020-10-19       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.